Trial Profile
A multicenter, randomized, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427, 857 [maraviroc], in combination with optimized background therapy versus optimized background therapy alone for the treatment of antiretroviral-experienced HIV-1 infected subjects.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 25 Oct 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms MOTIVATE-1
- Sponsors ViiV Healthcare
- 07 Oct 2021 Results assessing the lack of cross-resistance between the prodrug of temsavir (TMR) and ibalizumab or maraviroc from clinical samples from the BRIGHTE and MOTIVATE Phase 3 studies, published in the AIDS.
- 10 Mar 2021 Results of six envelopes derived from plasma samples from participants in the BRIGHTE study and 5 R5-tropic MVC-resistant envelopes from the MOTIVATE trials, assessing susceptibility to temsavir is not linked to Iba or Mvc resistance, presented at the 28th Conference on Retroviruses and Opportunistic Infections.
- 12 Sep 2015 Pooled analysis (SINGLE + MOTIVATE); Missing CD4+ cell response, results published in the HIV Clinical Trials.